KRAS and lung carcinoma: For example, Weng et al. [52] developed a DNA vaccine targeting kirsten rat sarcoma viral oncogene homolog (KRAS) driver mutations commonly found in lung cancer, which successfully induced antitumor immune responses in a murine model harboring this mutation, thereby validating the feasibility of targeting key oncogenes.